Group 1 - The Hong Kong stock market is experiencing volatility, with the pharmaceutical sector leading the decline, as the Hang Seng Biotechnology Index fell over 2% [1] - The Hong Kong ETFs focused on innovative drugs and CXO+AI healthcare, namely the Hang Seng Pharmaceutical ETF (159892) and the Hong Kong Stock Connect Medical ETF (520510), both dropped more than 2% [1] - Specific stocks such as Crystal International Holdings, 3SBio, MicroPort Scientific, WuXi AppTec, WuXi Biologics, and Innovent Biologics are among the biggest losers in the CXO and innovative drug sectors [1] Group 2 - According to China Merchants International, there is an expected explosive growth in outbound licensing transactions for innovative drugs by 2025, with several transactions already materializing in early 2026, indicating a high level of activity in China's innovative drug outbound licensing market [1]
港股医药大幅下挫，恒生医药ETF跌超2%
Mei Ri Jing Ji Xin Wen·2026-01-26 03:28